Sequence conservation of the region targeted by the abbott real time HBV viral load assay in clinical specimens

Journal of Clinical Microbiology

Volumn 51, Issue 4, 2013, Pages 1260-1262

  Cloherty, Gavin A ^a,e   Rhoads, James ^a   Young, Thomas P ^c   Parkin, Neil T ^b   Holzmayer, Vera ^d   Yuen, Lilly ^a   Mullen, Carolyn ^a  

^a Abbott Molecular Inc   (United States)

^b DATA FIRST CONSULTING INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ABBOTT DIAGNOSTICS   (United States)

^e Evivar Medical Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABBOTT REALTIME HBV VIRAL LOAD ASSAY; AMINO TERMINAL SEQUENCE; ARTICLE; ASSAY; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL; S GENE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; THERMODYNAMICS; VIRUS GENE; VIRUS GENOME;

BASE SEQUENCE; CONSERVED SEQUENCE; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; POLYMORPHISM, GENETIC; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 84875824209     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03003-12     Document Type: Article

References (24)

1. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 57:167-185.
2. Kurbanov F, Tanaka Y, Mizokami M. 2010. Geographical and genetic diversity of the human hepatitis B virus. Hepatol. Res. 40:14-30.
3. Echevarria JM, Avellon A. 2006. Hepatitis B virus genetic diversity. J. Med. Virol. 78(Suppl 1):S36-S42.
4. Hollinger FB. 2007. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J. Viral Hepat. 14(Suppl 1):11-15.
5. Hackett J, Jr. 2012. Meeting the challenge of HIV diversity: Strategies to mitigate the impact of HIV-1 genetic heterogeneity on performance of nucleic acid testing assays. Clin. Lab. 58:199-202.
6. Prange R, Nagel R, Streeck RE. 1992. Deletions in the hepatitis B virus small envelope protein: Effect on assembly and secretion of surface antigen particles. J. Virol. 66:5832-5841.
7. Bolivar H, Geffin R, Manzi G, Fischl MA, Holzmayer V, Mak WB, Abravaya K, Hackett J, Jr. 2009. The challenge of HIV-1 genetic diversity: Discordant CD4-T-cell count and viral load in an untreated patient infected with a subtype F strain. J. Acquir. Immune Defic. Syndr. 52:659-661.
8. Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, Brun-Vezinet F, Descamps D. 2007. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J. Clin. Microbiol. 45:3436-3438.
9. Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F. 2009. Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype Ginfected patient. J. Clin. Microbiol. 47:3763-3764.
10. Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M, Orani A, Rossotti R, Rossi D, Allain JP, Prati D. 2011. A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 51: 719-730.
11. Holguin A, Lopez M, Molinero M, Soriano V. 2008. Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J. Clin. Microbiol. 46:2918-2923.
12. Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, Taylor N, Eberle J. 2009. Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J. Clin. Microbiol. 47:1238-1240.
13. Lataillade M, Chiarella J, Kozal MJ. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
14. Lindh M, Hannoun C, Malmstrom S, Lindberg J, Norkrans G. 2006. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay. J. Clin. Microbiol. 44:2587-2589.
15. Metifiot M, Marchand C, Maddali K, Pommier Y. 2010. Resistance to integrase inhibitors. Viruses 2:1347-1366.
16. Pyne MT, Brown KL, Hillyard DR. 2010. Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test and identification of rare polymorphisms potentially affecting assay performance. J. Clin. Microbiol. 48: 2852-2858.
17. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
18. Swanson P, Holzmayer V, Huang S, Hay P, Adebiyi A, Rice P, Abravaya K, Thamm S, Devare SG, Hackett J, Jr. 2006. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: Comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA quantitative assays. J. Virol. Methods 137:184-192.
19. Swanson P, Huang S, Abravaya K, de Mendoza C, Soriano V, Devare SG, Hackett J, Jr. 2007. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J. Virol. Methods 141:49-57.
20. Swanson P, Huang S, Holzmayer V, Bodelle P, Yamaguchi J, Brennan C, Badaro R, Brites C, Abravaya K, Devare SG, Hackett J, Jr. 2006. Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J. Virol. Methods 134:237-243.
21. Tang N, Huang S, Salituro J, Mak WB, Cloherty G, Johanson J, Li YH, Schneider G, Robinson J, Hackett J, Jr, Swanson P, Abravaya K. 2007. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse groupMsubtypes A-H, group O and group N samples. J. Virol. Methods 146:236-245.
22. von Truchsess I, Harris B, Schatzl HM, Hackett J, Jr. 2006. The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. J. Med. Virol. 78:311-317.
23. Yotsumoto M, Shinozawa K, Yamamoto Y, Sugiura W, Miura T, Fukutake K. 2011. Mutations to the probe of Cobas TaqMan HIV-1 ver. 1.0 assay causing undetectable viral load in a patient with acute HIV-1 infection. J. Infect. Chemother. 17:863-865.
24. Ciotti M, Marcuccilli F, Guenci T, Prignano MG, Perno CF. 2008. Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B. J. Clin. Microbiol. 46:1517-1519.